Pharmasol Corporation Warning Letter Details

Summary

Based on limited metadata, this FDA Warning Letter issued to Pharmasol Corporation on March 14, 2019, concerns drug manufacturing or distribution practices. Without access to the full letter text or a detailed subject line, the specific regulatory violations cannot be determined, though FDA Warning Letters typically address manufacturing, labeling, marketing, or quality control deficiencies. The letter falls under FDA's drug regulatory authority, though the specific issuing office is not identified in the available metadata. To understand the precise nature of the compliance issues and required corrective actions, review of the complete warning letter would be necessary.